News for CATB Stock

Catabasis Pharmaceuticals Announces New Company Name, Astria Therapeutics, Highlighting New Company Focus Catabasis Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides a Corporate Update Catabasis Pharmaceuticals to Present at 2021 Wedbush PacGrow Healthcare Conference Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences  Catabasis Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides a Corporate Update Catabasis Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides a Corporate Update Catabasis Pharmaceuticals To Present At Upcoming Investor Conferences    Catabasis Pharmaceuticals Announces Acquisition of Quellis Biosciences Inc. Catabasis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides a Corporate Update Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy Catabasis Pharmaceuticals Presents Information on Edasalonexent, a Potential Foundational Therapy for Duchenne Muscular Dystrophy, at the Virtual 25th International Congress of the World Muscle Society